This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Review paper

Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension

Volume: 115, Issue: 5, Pages: 904 - 914
Published: Jan 25, 2019
Abstract
Since the formation of new blood vessels is essential for tumour growth and metastatic spread, inhibition of angiogenesis by targeting the vascular endothelial growth factor (VEGF) pathway is an effective strategy for various types of cancer, most importantly renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. However, VEGF inhibitors have serious side effects, most importantly hypertension and nephropathy. In case of fulminant...
Paper Details
Title
Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension
Published Date
Jan 25, 2019
Volume
115
Issue
5
Pages
904 - 914
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.